If you shift your view and look at it as a turnaround stock, it could be worth buying. The high yield, in this case, is ...

Pfizer Inc. (NYSE:PFE) is one of the Most Undervalued Long Term Stocks to Buy Right Now. On October 19, Pfizer Inc. (NYSE:PFE ...

If you’re eyeing Pfizer stock and wondering what’s next, you’re definitely not alone. The last few years have been a roller ...

Pfizer (PFE) offers potential 20-30% upside despite revenue risks. Explore its valuation, pipeline prospects, and dividend ...

These high-yielding S&P 500 stocks offer incredible, dependable yields from quality blue-chip companies you can buy and hold ...

But the two have racked up an astronomical, nine-figure legal bill that far exceeds any reasonable amount the two may have ...

Pfizer (PFE) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of ...

Pfizer Inc. is a global biopharmaceutical leader with a diversified product portfolio and significant scale, supported by annual revenue of $63.9 billion (TTM). Its extensive distribution network and ...

Nine of fifteen Barron's Better Bets (BBB) 'safer' high-yield dividend stocks are currently attractively priced, including ...

Conservative outlooks while a U.S. government shutdown drags on could present an opportunity to buy aerospace and defense ...

Cohen's Point72 purchased over 8 million shares of C4 Therapeutics within weeks of the company announcing phase 1 trial data ...

According to TipRanks.com, Schott is a 3-star analyst with an average return of 1.9% and a 53.1% success rate. Schott covers the Healthcare sector, focusing on stocks such as Amneal Pharmaceuticals, ...